JP2023528206A5 - - Google Patents

Info

Publication number
JP2023528206A5
JP2023528206A5 JP2022568691A JP2022568691A JP2023528206A5 JP 2023528206 A5 JP2023528206 A5 JP 2023528206A5 JP 2022568691 A JP2022568691 A JP 2022568691A JP 2022568691 A JP2022568691 A JP 2022568691A JP 2023528206 A5 JP2023528206 A5 JP 2023528206A5
Authority
JP
Japan
Prior art keywords
cancer
seq
modified immune
cells
hla
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022568691A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023528206A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2021/051157 external-priority patent/WO2021229234A1/en
Publication of JP2023528206A publication Critical patent/JP2023528206A/ja
Publication of JP2023528206A5 publication Critical patent/JP2023528206A5/ja
Pending legal-status Critical Current

Links

JP2022568691A 2020-05-13 2021-05-13 癌または腫瘍の治療方法 Pending JP2023528206A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063024077P 2020-05-13 2020-05-13
US63/024,077 2020-05-13
US202063030503P 2020-05-27 2020-05-27
US63/030,503 2020-05-27
US202063089611P 2020-10-09 2020-10-09
US63/089,611 2020-10-09
PCT/GB2021/051157 WO2021229234A1 (en) 2020-05-13 2021-05-13 Method of treatment of cancer or tumour

Publications (2)

Publication Number Publication Date
JP2023528206A JP2023528206A (ja) 2023-07-04
JP2023528206A5 true JP2023528206A5 (enExample) 2025-03-28

Family

ID=76098970

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022568691A Pending JP2023528206A (ja) 2020-05-13 2021-05-13 癌または腫瘍の治療方法

Country Status (7)

Country Link
US (1) US20230190803A1 (enExample)
EP (1) EP4149493A1 (enExample)
JP (1) JP2023528206A (enExample)
CN (1) CN116264826A (enExample)
AU (1) AU2021272400A1 (enExample)
CA (1) CA3178582A1 (enExample)
WO (1) WO2021229234A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021208433A1 (en) * 2020-01-14 2022-07-14 Uswm Ct, Llc Method of treatment of cancer or tumour
US12435444B2 (en) 2021-03-09 2025-10-07 Cdr-Life Ag Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same
EP4304726A1 (en) 2021-03-09 2024-01-17 CDR-Life AG Mage-a4 peptide-mhc antigen binding proteins
GB202213052D0 (en) * 2022-09-07 2022-10-19 Adaptimmune Ltd Method and treatment of bladder cancer
GB202213051D0 (en) * 2022-09-07 2022-10-19 Adaptimmune Ltd Method of treatment of head and neck cancer
EP4587046A1 (en) 2022-09-14 2025-07-23 CDR-Life AG Mage-a4 peptide dual t cell engagers

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102719401B (zh) * 2012-07-05 2014-04-23 时宏珍 Hla-a0201限制性抗mage抗原特异性ctl的制备方法
US20190038713A1 (en) * 2015-11-07 2019-02-07 Multivir Inc. Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
WO2017112944A1 (en) * 2015-12-23 2017-06-29 Fred Hutchinson Cancer Research Center High affinity t cell receptors and uses thereof
MX2018012265A (es) * 2016-04-08 2019-02-07 Adaptimmune Ltd Receptores de celulas t.
GB201616238D0 (en) * 2016-09-23 2016-11-09 Adaptimmune Ltd Modified T cells
GB201819540D0 (en) * 2018-11-30 2019-01-16 Adaptimmune Ltd T cell modification
AU2021208433A1 (en) * 2020-01-14 2022-07-14 Uswm Ct, Llc Method of treatment of cancer or tumour

Similar Documents

Publication Publication Date Title
JP2023526259A5 (enExample)
Kishore et al. Current advancements and future perspectives of immunotherapy in colorectal cancer research
Mathew et al. Combining chemotherapy with PD-1 blockade in NSCLC
Duffy et al. Immunological off-target effects of standard treatments in gastrointestinal cancers
TW201545759A (zh) 用於治療非小細胞肺癌之抗ｂ７－ｈ１及抗ｃｔｌａ－４抗體
Rivera Vargas et al. Can immunogenic chemotherapies relieve cancer cell resistance to immune checkpoint inhibitors?
US20230190802A1 (en) Method of treatment of cancer or tumour
AU2026201847A1 (en) Methods, therapies and uses for treating cancer
WO2019014468A1 (en) RECEPTOR SUBTYPE AND RETINOID COMPOUNDS AND SELECTIVE REXINOIDS OF A FUNCTION IN COMBINATION WITH IMMUNE MODULATORS FOR ANTICANCER IMMUNOTHERAPY
BR112016024972B1 (pt) Anticorpo monoclonal humanizado, polinucleotídeo isolado,plasmídeo, composições farmacêutica e de disgnóstico, usos do dito anticorpo monoclonal humanizado e método in vitro para determinar a expressão de ceacam1
Miljkovic et al. Interleukin-15 augments NK cell–mediated ADCC of alemtuzumab in patients with CD52+ T-cell malignancies
US10980859B2 (en) In vivo individualized systemic immunotherapeutic method and device
US12565528B2 (en) LAG-3 antagonist therapy for lung cancer
JP2026028258A (ja) 併用処置
Terlecka et al. LAG-3 as a therapeutic target in melanoma
Sarkisian et al. Current clinical trials in the treatment of advanced melanomas
WO2024081858A1 (en) Kras/tp53 neoantigen specific t cell receptors
JP2025516676A (ja) 個別化されたがんエピトープ及びそれを使用する方法
JP2024513915A (ja) 二重特異性ｔ細胞エンゲージャーの投与方法
US20230181633A1 (en) Methods of treating cancer using a combination of tumor membrane vesicles and metformin
WO2022099006A1 (en) Assessment of cancers for treatment with a cd33/cd3 bispecific t cell engager
WO2022046833A1 (en) Methods of treating cancer by administering a pd-1 inhibitor
JP2023513350A5 (enExample)
CA2464947C (en) Combination therapy for treating disease
US20240016844A1 (en) Methods of treatment using a genetically modified autologous t cell immunotherapy